Cite this answer
Retatrutide vs Tirzepatide: Triple vs Dual Agonist for Weight Loss: quick citable summary
This PeptaHub comparison summarizes Retatrutide and Tirzepatide side by side, covering category, legal status, primary route, half-life, mechanism, and editorial verdict for writers and AI answer engines.
PeptaHub. “Retatrutide vs Tirzepatide: Triple vs Dual Agonist for Weight Loss.” peptahub.com, 2026. https://peptahub.com/compare/retatrutide-vs-tirzepatide. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/compare/retatrutide-vs-tirzepatide.
Head-to-head comparison
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Legal Status | Research Only | Prescription |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~6 days | ~5 days |
| Mol. Weight | 4,894.58 Da | 4,813.45 Da |
| Side Effects | Nausea (most common, dose-dependent), Vomiting, Diarrhea | Nausea (up to 31%), Diarrhea, Vomiting |
Key differences
- Receptor targets: Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist; tirzepatide is a dual GLP-1/GIP receptor agonist.
- Weight loss efficacy: Phase 3 TRIUMPH-1 topline data reported retatrutide (12 mg) achieved 28.3% mean weight loss at 80 weeks, with about 45% reaching at least 30%; tirzepatide (15 mg) achieved 22.5% at 72 weeks in Phase III SURMOUNT trials.
- Glucagon component: Retatrutide's glucagon receptor agonism increases energy expenditure and hepatic fat oxidation, a mechanism tirzepatide lacks.
- Approval status: Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity); retatrutide has Phase 3 topline data but remains investigational with no FDA approval yet.
- Manufacturer: Retatrutide is developed by Eli Lilly, the same company behind tirzepatide, suggesting a potential pipeline succession.
- Liver fat reduction: Retatrutide Phase II data showed significant liver fat reduction, potentially relevant for MASH/NAFLD; tirzepatide also shows liver fat benefits but through fewer receptor pathways.
- Safety profile: Retatrutide Phase II showed GI side effects similar to tirzepatide; long-term Phase III safety data is pending.
The verdict
Retatrutide's Phase 3 TRIUMPH-1 topline data suggests it may eventually surpass tirzepatide as the most effective weight loss medication, with the added glucagon receptor providing metabolic benefits tirzepatide lacks. However, tirzepatide is FDA-approved and commercially available today with extensive Phase III safety data, while retatrutide remains investigational and not FDA-approved. For current clinical use, tirzepatide is the established option; retatrutide is a pipeline contender awaiting full regulatory review.
Frequently asked questions
Phase 3 TRIUMPH-1 topline data reported 28.3% mean weight loss at 80 weeks with retatrutide 12 mg, and about 45% of participants reached at least 30% weight loss, versus tirzepatide's 22.5% at 72 weeks in SURMOUNT-1. This is not a head-to-head comparison, and trial designs differ. Tirzepatide is FDA-approved; retatrutide remains investigational and not FDA-approved.
Retatrutide is currently in Phase III clinical trials conducted by Eli Lilly. If trials succeed, FDA approval could follow, but specific timelines are not confirmed. Tirzepatide is available now by prescription.
The glucagon receptor component increases energy expenditure and stimulates hepatic fat oxidation, potentially providing additional weight loss and liver fat reduction beyond what GLP-1/GIP dual agonism achieves alone. This is the key differentiator from tirzepatide.
Yes, both are developed by Eli Lilly. Retatrutide is positioned as a potential next-generation therapy that could succeed or complement tirzepatide in Lilly's obesity pipeline.
Phase II data showed similar GI side effect profiles (nausea, vomiting, diarrhea). The glucagon component raises theoretical concerns about hepatic effects, but Phase II safety data was acceptable. Comprehensive safety comparison requires Phase III data, which is ongoing.